Tamoxifen prevents sulpiride-induced weight gain in female rats

Pharmacology Biochemistry and Behavior

Volumn 57, Issue 1-2, 1997, Pages 215-222

  Baptista, Trino ^a,b,c   De Baptista, Enma Araujo ^a   Hernandez, Luis ^a   Altemus, Marty ^b   Weiss, Susan R ^b  

^a UNIVERSIDAD DE LOS ANDES   (Venezuela)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NONE   (Venezuela)

Author keywords

Bromocriptine; Estradiol; Neuroleptics; Obesity; Rats; Sulpiride; Tamoxifen

Indexed keywords

BROMOCRIPTINE; ESTRADIOL; NEUROLEPTIC AGENT; PROLACTIN; SULPIRIDE; TAMOXIFEN CITRATE;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ESTRADIOL BLOOD LEVEL; FEMALE; FOOD INTAKE; HYPERPHAGIA; HYPERPROLACTINEMIA; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RAT; WEIGHT GAIN;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTIPSYCHOTIC AGENTS; DRUG EVALUATION, PRECLINICAL; EATING; ESTROGEN ANTAGONISTS; FEMALE; RATS; RATS, SPRAGUE-DAWLEY; SULPIRIDE; TAMOXIFEN; WEIGHT GAIN;

ANIMALIA;

EID: 0030938038     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(96)00315-2     Document Type: Article

References (59)

1. Ahdieh, H. B.; Mayer, A. D.; Rosenblatt, J. S. Effects of brain antiestrogen implants on maternal behavior and postpartum estrous in pregnant rats. Neuroendocrinol. 46:522-531; 1987.
2. Ataya, K.; Mercado, A.; Kartaginer, J.; Abbasi, A.; Moghissi, K. S. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil. & Steril. 50:876-881; 1988.
3. Baptista, T.; Hernandez, L. Efecto de los neurolepticos sobre el peso corporal de ratas. Resumenes de la 31a Convencion Anual de ASOVAC. Caracas, Venezuela, pp. 104; 1983.
4. 2 dopamine receptors involved? Pharmacol. Biochem. Behav. 27:399-405; 1987.
5. Baptista, T.; Parada, M. A.; Murzi, E. Puberty modifies sulpiride effects on body weight in rats. Neurosci Lett. 92:161-164; 1988.
6. 2 dopamine receptors supersensitivity? Med. Hypoth. 30:5-8; 1989.
7. Baptista, T.; Teneud, L.; Hernandez, L. Enhancement of amphetamine anorexia after chronic administration of sulpiride in rats. Pharmacol. Biochem. Behav. 45:45-49; 1993a.
8. Baptista, T.; Mata, A.; Teneud, L.; De Quijada, M.; Han Hui-Wan.; Hernandez, L. Effects of longer-term administration of clozapine on body weight and food intake in rats. Pharmacol. Biochem. Behav. 45:51-54; 1993b.
9. Baptista, T.; Teneud, L.; Alastre, T.; Contreras, Q.; Burguera, J. L.; Burguera, M.; Baptista, E.; Weiss, S.; Hernandez, L. Lithium and Weight Gain. Pharmacopsychiat. 28:35-44; 1995.
10. Bernstein, J. G. Psychotropic drug induced weight gain: mechanisms and management. Clin. Neuropharmacol. 11:S194-S206; 1988.
11. Beumont, P. J. V.; Gelder, M. G.; Friesen, H. G. Harris, G. W. MacKinnon, P. C. B.; Mandelbrote, B. M.; Wiles, D. H. The effects of phenothiazines on endocrine function: I Patients with inappropriate lactation and amenorrhoea, Brit. J. Psychiat. 124: 413-419; 1974a.
12. Beumont, P. J. V.; Corker, C. S.; Friesen, H. G.; Kolawkowska, T.; Mandelbrote, B. M.; Marshall, J.; Murray, M. A. F.; Wiles, D. H. The effects of phenothiazines on endocrine function: II Effects in men and post-menopausal women. Brit. J. Psychiat. 124:420-430; 1974b.
13. Bowman, S. P.; Jones, C. A. Leake, A.; Morris, I. D. The biological activity of a single dose of tamoxifen in the adult ovariectomized rat. Br. J. Pharmac. 78:617-622; 1983.
14. Brown, M. Estrogen receptor molecular biology. Hematol/Oncol. Clin. North. Amer. 8:101-112; 1994.
15. Calabresi, P.; Chabner B. A. Quimioterapia de las Enfermedades Neoplásicas. In: Gilman A.; Gilman, Th.; Rail, W.; Niese, A. S. Taylor, P.; eds. Las Bases Farmacologicas de la Terapeutica. Mexico: Editorial Médica Panamericana; 1991; 1163-1222.
16. Correa, N.; Opler, L. A.; Kay, S. R.; Birmaher, B. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J. Clin. Psychopharmacol. 7:91-95; 1987.
17. Daniels, G. H.; Martin, J. B. Neuroendocrine regulation and diseases of the anterior pituitary and hypothalamus. In: Isselbacher, K. J.; Braunwald, E.; Wilson, J. D.; Martin, J. B.; Fauci, A. S.; Kasper, D. L. eds. Harrison's Principles of Internal Medicine. New. New York: McGraw-Hill, Inc.; 1994; 1891-1918.
18. Davis, J. M.; Barter, J. T.; Kane, J. M. Antipsychotic drugs. In: Kaplan, H. I.; Sadock, B. J. eds. Comprehensive Textbook of Psychiatry/V. Baltimore: Williams & Wilkins, 1989; 1626.
19. Di Paolo, T. H.; Falardeau, P. Modulation of brain and pituitary dopamine receptors by estrogens and prolactin. Prog. Neuropsychopharmacol. & Biol. Psychiat. 9:473-480; 1985.
20. Dolin, R. Antiviral chemotherapy. In: Isselbacher, K. J.; Braunwlad, E.; Wilson, J. D.; Martin, J. B.; Fauci, A. S.; Kasper, D. L., eds. Harrison's Principles of Internal Medicine. New York: McGraw-Hill, Inc; 1994; 776-782.
21. Donohoe, T. P.; Stevens. R. Modulation of food intake by hypothalamic implants of estradiol benzoate, estrone, estriol, and CI-628 in female rats. Pharmacol. Biochem. Behav. 19:93-99; 1982.
22. Dorevitch, A.; Aronzon R.; Starck, M. Psychotic exacerbation attributed to low dose bromocriptine treatment of galactorrea and hyperprolactinemia. Acta Obstr. Gynecol. Scand. 70:375-376; 1991.
23. Earley, C. J.; Leonard, B. E. Androgens, estrogens and their antihormones: effects on body weight and food consumption. Pharmacol. Biochem. Behav. 11:211-214; 1979.
24. Fornander, T.; Rutqvist, L. E.; Wilking, N.; Carlstrom, K.; Schoultz, B. Oestrogenic effects of adjuvant tamoxifen in postmenopausal breast cancer. Eur. J. Cancer. 29A:497-500; 1993.
25. Frye, P. E.; Pariser, S. E.; Kim, M. H.; O'Shaughnessy, R. W. Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia. J. Clin. Psychiat. 43:252-253; 1982.
26. Goplaswamy, A. L.; Morgan. R. Too many chronic mentally disabled patients are too fat. Acta Psychiat. Scand. 72:254-258; 1985.
27. Gray, J. M.; Wade. G. N. Food intake, body weight, and adiposity in female rats: Actions and interactions of progestins and antiestrogens. Am. J. Physiol. 240:E474-E481; 1981.
28. Gray, J. M.; Schrock, S.; Bishop, M. Estrogens and antiestrogens: actions and interactions with fluphenazine on food intake and body weight in rats. Am. J. Physiol. 264:R1214-1218; 1993.
29. Groom, C. V.; Griffiths, K. Effect of the antiestrogen tamoxifen on plasma levels of luteinizing hormone, follicle stimulating hormone, prolactin, oestradiol and progesterone in normal premenopausal women. J. Endocrinol. 70:421-428; 1976.
30. Jordan, V. C.; Allen, K. E.; Dix, C. J. The pharmacology of tamoxifen in laboratory animals. Cancer Treat. Rep. 64:745; 1980.
31. Jordan, V. C.; Fritz, N. F.; Tormey, D. C. Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node positive patients with breast cancer. Cancer Res. 47:624-630; 1987.
32. Jordan, V. C.; Murphy, C. S. Endocrine pharmacology of antiestrogens as antitumor agents. Endrocr. Rev. 11:578-610; 1990.
33. Jordan, V. C. A current view of tamoxifen for the treatment and prevention of breast cancer. Brit. J. Pharmacol. 110(2):507-518; 1993.
34. Kebabian, J. W.; Calne, D. B. Multiple receptors for dopamine. Nature. 277:93-96; 1975.
35. Komisaruk, B.; Beyer, C. Differential antagonism by MER-25 of behavioral and morphological effects of estradiol benzoate in rats. Horm. Behav. 3:63-70; 1972.
36. Korach, K. S. Insights from the study of animals lacking functional estrogen receptor. Science. 266:1524-1527; 1994.
37. Maentausta, O.; Svalander, P.; Danielsson, K. G.; Bygdeman, M.; Vihko, R. The effects of an antiprogestin, mifepristone, and an antiestrogen, tamoxifen, on endometrial 17 beta-hydroxysteroid dehydrogenase and progestin and estrogen receptors during the luteal phase of the menstrual cycle: an immunohistochemical study. J. Clin. Endocrinol. Metab. 77:913-918; 1993.
38. Moore, B. J.; Gerardo-Gettens, T.; Horwitz, B. A.; Stern, J. S. Hyperprolactinemia stimulates food intake in the female rat. Brain. Res. Bull. 17:563-569; 1986.
39. Nestelbaum, Z.; Siris, S. G.; Rifkin, A.; Klar, H.; Reardon, G. T. Exacerbation of schizophrenia associated with amantadine. Am J Psychiatry 143:1170-1171, 1986.
40. Oades, R. D.; Schepker, R. Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinol. 19:373-385; 1994.
41. Parada, M. A.; Hernandez, L.; Paez, X.; Baptista, T.; Puig de Parada, M.; Quijada, M. Mechanism of the sulpiride-induced obesity. Pharmacol. Biochem. Behav. 33:45-50; 1989.
42. 2 satiety receptors in the body weight increase induced by systemic sulpiride. Physiol. Behav. 50:1161-1165; 1991.
43. Peter, S. A.; Autz, A.; Jean-Simon, M. L. Bromocriptine-induced schizophrenia. J. Nat. Med. Assoc. 85:700-701; 1993.
44. Ron, I. G.; Inbar, M. J.; Barak, Y.; Stier, S.; Chaitchick, S. Organic delusional syndrome associated with tamoxifen treatment. Cancer 69:1415, 1992.
45. Rose, D. P.; Davis, T. E. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res. 40:4043-4047; 1980.
46. Rose, D. P.; Connolly, J. M.; Chlebowski, R. T.; Buzzard, I. M.; Wynder, E. L. The effects of a low-fat dietary intervention and tamoxifen adjuvant therapy on the serum estrogen and sex hormone-binding globulin concentrations of postmenopausal breast cancer patients. Breast Cancer Res. Treat. 27:253-262; 1993.
47. Roy, E. J.; Maas, C. A.; Wade. G. N. Central actions and a species comparison of the estrogenic effects of an antiestrogen on eating and body weight. Physiol. Behav. 18:137-140; 1977.
48. Roy, E. J.; Wade, G. N. Estrogenic effects of an antiestrogen, MER-25, on eating and body weight in rats. J. Comp. Physiol. Psychol. 90:156-166; 1976.
49. Sawka, C. A.; Pritchard, K. I.; Paterson, A. H. G.; Sutherland, D. J. A.; Thomson, D. B.; Shelley, W. E.; Myers, R. E.; Mobbs, B. G.; Malkin, W. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res. 46:3152-3156; 1986.
50. Segal, D. S.; Janowsky, D. S. Psychoestimulant-induced behavioral effects: possible models of schizophrenia. In: Lipton, M. A.; Di Mascio, A.; Killman, K. F. eds. Psychopharmacology: A generation of progress. New York: Raven Press; 1978:1113-1124.
51. Simpsom, G.; Pi, E. H.; Sramek, J. J. Adverse effects of antipsychotic agents. Drugs 21:138-151; 1981.
52. Teneud, L.; Lopez, M. A.; Contreras, Q.; Alastre, T.; Weiss, S. R. B.; Altemus, M.; Hernandez L.; Baptista, T. Amantadine does not prevent neuroleptic-induced obesity in rats. Neuroscience Annual Meeting, San Deigo, CA, 1995, pp. 1462.
53. Tsai-Morris, C. H.; Ghosh, M.; Hirschfield, A. N.; Wise, P. M.; Brodie, A. M. H. Inhibition of ovarian aromatase by prolactin in vivo. Biol. Reprod. 29:342-346; 1983.
54. Van Leeuwen, F. E.; Beenraadt, J.; Coebergh, J. W. W.; Kiemeney, A. L. M.; Gimbrere, C. H. F.; Otter, R.; Schouten, L. J.; Damhuis, R. A. M.; Bontenbal, M.; Diepenhorst, F. W.; Van Den Belt-Dusebout, A. W.; Van Tinteren, H. Risk of endometrial cancer after tamoxifen treatment of breast cancer. The Lancet. 343: 448-452; 1994.
55. Wade, G. N.; Gray, J. M. Gonadal effects on food intake and adiposity: a metabolic hypothesis. Physiol Behav. 22:583-594; 1979.
56. Wade, G. N.; Heller, H. W. Tamoxifen mimics the effects of estradiol on food intake, body weight, and body composition in rats. Am. J. Physiol. 264:1219-1223; 1993.
57. Wade, G. N.; Schneider, J. E. Metabolic fuels and reproduction in female mammals. Neurosci. Behav. Rev. 16:235-272; 1992.
58. Wang, C.; Hsueh, A. J. W.; Erikson, G. F. Prolactin inhibition of estrogen production by cultured rat granulosa cell. Mol. Cell. Endocrinol. 20:135, 1980.
59. Willis, K. J.; London, D. R.; Wardtt, W. C.; But, W. R.; Lynch, S. S.; Rudd, B. T. Recurrent breast cancer treated with the antiestrogen tamoxifen correlation between hormonal changes and clinical course. Br. Med. J. 425-428; 1977.